UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.052

Sortiert nach

Overview upon miR-21 in lung cancer: focus on NSCLC

Cellular and molecular life sciences : CMLS, 2018-10, Vol.75 (19), p.3539-3551

2018

Volltextzugriff (PDF)

182P Impact of SARS CoV 2 outbreak in the molecular diagnosis of advanced NSCLC: A retrospective comparative cohort study

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S796-S797

2021

Volltextzugriff (PDF)

179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S794-S795

2021

Volltextzugriff (PDF)

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S795-S795

2021

Volltextzugriff (PDF)

Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer

European journal of medicinal chemistry, 2024-11, Vol.277, p.116711, Article 116711

2024

Volltextzugriff (PDF)

Programmed death ligand-1 expression in non-small cell lung cancer

Laboratory investigation, 2014-01, Vol.94 (1), p.107-116

2014

Volltextzugriff (PDF)

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Lung cancer (Amsterdam, Netherlands), 2024-08, Vol.194, p.107865, Article 107865

2024

Volltextzugriff (PDF)

Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations

Journal of thoracic oncology, 2024-06

2024

Volltextzugriff (PDF)

The Peninsula stage III non-small cell lung cancer audit: assessing the impact of COVID-19 on treatment decisions

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S27-S27

2023

Volltextzugriff (PDF)

Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

European journal of cancer (1990), 2024-09, Vol.208, p.114182, Article 114182

2024

Volltextzugriff (PDF)

Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer

Journal of the Formosan Medical Association, 2024-08, Vol.123 (8), p.875-881

2024

Volltextzugriff (PDF)

Mutant p53 achieves function by regulating EGR1 to induce epithelial mesenchymal transition

Tissue & cell, 2024-10, Vol.90, p.102510, Article 102510

2024

Volltextzugriff (PDF)

Video-assisted mediastinoscopic lymphadenectomy (VAMLA): Mature results for staging non–small cell lung cancer with normal mediastinum

The Journal of thoracic and cardiovascular surgery, 2024-02

2024

Volltextzugriff (PDF)

Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1

Biochemical and biophysical research communications, 2018-03, Vol.497 (4), p.1003-1010

2018

Volltextzugriff (PDF)

Disulfiram/copper complex improves the effectiveness of the WEE1 inhibitor Adavosertib in p53 deficient non-small cell lung cancer via ferroptosis

Biochimica et biophysica acta. Molecular basis of disease, 2024-08, p.167455, Article 167455

2024

Volltextzugriff (PDF)

Circ_0006949 as a potential non-invasive diagnosis biomarker promotes the proliferation of NSCLC cells via miR-4673/GLUL axis

Biochimica et biophysica acta. Molecular basis of disease, 2024-08, Vol.1870 (6), p.167234, Article 167234

2024

Volltextzugriff (PDF)

Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC

Journal of thoracic oncology, 2024-05

2024

Volltextzugriff (PDF)

Non-small cell lung cancer: current treatment and future advances

Translational lung cancer research, 2016-06, Vol.5 (3), p.288-300

2016

Volltextzugriff (PDF)

MicroRNA-522-3p promotes brain metastasis in non-small cell lung cancer by targeting Tensin 1 and modulating blood-brain barrier permeability

Experimental cell research, 2024-08, p.114199, Article 114199

2024

Volltextzugriff (PDF)

PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression

Oncotarget, 2018-01, Vol.9 (4), p.4637-4646

2018

Volltextzugriff (PDF)

CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer

Oncoimmunology, 2017-06, Vol.6 (6), p.e1320011-e1320011

2017

Volltextzugriff (PDF)

Outcomes analysis of patients receiving local ablative therapy for oligoprogressive metastatic NSCLC under first-line immunotherapy

Clinical lung cancer, 2024-08

2024

Volltextzugriff (PDF)

Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non–small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing

The Journal of thoracic and cardiovascular surgery, 2024-04

Lee, Jay M.

2024

Volltextzugriff (PDF)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Journal of experimental & clinical cancer research, 2017-12, Vol.36 (1), Article 174

2017

Volltextzugriff (PDF)

1 – 25 von 2.052

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.545)
Mit Volltextzugriff
(1.869)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Nsclc
(1.338)
Lung Cancer
(475)
Humans
(444)
Non-Small Cell Lung Cancer
(363)
Chemotherapy
(210)
Lung Neoplasms - Drug Therapy
(200)
Lung Neoplasms - Pathology
(200)
Science & Technology
(195)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(194)
Male
(192)
Female
(188)
Carcinoma, Non-Small-Cell Lung - Pathology
(182)
Oncology
(164)
Immunotherapy
(162)
Non-Small Cell Lung Carcinoma
(158)
Middle Aged
(155)
Aged
(147)
Tumors
(146)
Prognosis
(131)
Mutation
(126)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Lung Cancer
(66)
Oncotarget
(57)
Zhongguo Fei Ai Za Zhi
(50)
Frontiers In Oncology
(45)
The Chinese-German Journal Of Clinical Oncology
(44)
Heliyon
(41)
中国肺癌杂志
(39)
Cancer Treatment And Research Communications
(38)
Clinical Lung Cancer
(36)
肺癌
(35)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Overview upon miR-21 in lung cancer: focus on NSCLC

182P Impact of SARS CoV 2 outbreak in the molecular diagnosis of advanced NSCLC: A retrospective comparative cohort study

179P Efficacy and safety of extended-interval dosing strategy of immune checkpoint inhibitors during the COVID-19 outbreak: Experience from a single center

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer

Programmed death ligand-1 expression in non-small cell lung cancer

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations

The Peninsula stage III non-small cell lung cancer audit: assessing the impact of COVID-19 on treatment decisions

Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer

Mutant p53 achieves function by regulating EGR1 to induce epithelial mesenchymal transition

Video-assisted mediastinoscopic lymphadenectomy (VAMLA): Mature results for staging non–small cell lung cancer with normal mediastinum

Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1

Disulfiram/copper complex improves the effectiveness of the WEE1 inhibitor Adavosertib in p53 deficient non-small cell lung cancer via ferroptosis

Circ_0006949 as a potential non-invasive diagnosis biomarker promotes the proliferation of NSCLC cells via miR-4673/GLUL axis

Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC

Non-small cell lung cancer: current treatment and future advances

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

MicroRNA-522-3p promotes brain metastasis in non-small cell lung cancer by targeting Tensin 1 and modulating blood-brain barrier permeability

PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression

CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer

Outcomes analysis of patients receiving local ablative therapy for oligoprogressive metastatic NSCLC under first-line immunotherapy

Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non–small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Aktive Filter

Suchergebnisse filtern